Inspire Medical Systems' Reimbursement Headwinds May Affect 2026 Revenue, RBC Says
MT Newswires Live
Jan 28
Inspire Medical Systems (INSP) Inspire V device could be less utilized because of Medicare reimbursement uncertainty, RBC Capital Markets said in a note Tuesday.
A coding error at the Centers for Medicare & Medicaid Services has created a "physician disincentive," RBC said, as doctors will be paid less to perform Insipre V procedures.
"We are downgrading INSP following our Expert checks suggesting
Inspire V coding headwinds are likely to persist," RBC said, lowering its 2026 revenue estimate to $985.3 million from $1.01 billion.
RBC cut its rating on the stock to sector perform from outperform and reduced its price target to $90 from $175.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.